In conclusion, our data indicated that raltegravir reversed the breakdown of VE-cadherin- and claudin 18.1-containing endothelial adherens junctions both in vitro and in vivo, thereby restoring endothelial barrier integrity and reducing ALI-associated vascular permeability. The gene discussed is CDH5; the disease is acute respiratory distress syndrome.